Perl Alexander E
Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Blood Adv. 2017 Nov 14;1(24):2281-2294. doi: 10.1182/bloodadvances.2017009829.
Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration's approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulation of daunorubicin/cytarabine (CPX-351/Vyxeos), the standard of care is changing rapidly in AML for subgroups. This review will focus on currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment.
2017年，急性髓系白血病（AML）的药物治疗终于发生了重大变革。这是由于美国食品药品监督管理局批准了几种新型靶向药物（米哚妥林、恩杂鲁胺和吉妥珠单抗奥唑米星）。再加上最近批准的柔红霉素/阿糖胞苷新型脂质体制剂（CPX-351/Vyxeos），AML各亚组的治疗标准正在迅速改变。本综述将重点关注目前已获批的药物以及正在研发的有前景的新型药物，并将突出靶向治疗中的争议领域。
